| 2025-11-18 |
详情>>
业绩披露：
2025年中报每股收益17.92美元,归母净利润-932.8万美元,同比去年增长-171.01%
|
| 2025-07-22 |
详情>>
业绩披露：
2024年年报每股收益-26.94美元,归母净利润-628.4万美元,同比去年增长-22.69%
|
| 2025-05-21 |
股东大会：
将于2025-06-25召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Mr. Alon Dayan, Mr. Moshe Revach and Mr. Lior Vider to serve as Class II directors of the Company, until the Company’s third annual general meeting of shareholders following this Meeting, and until their respective successor is duly elected and qualified;
2.To approve an increase to the Company’s authorized share capital and to amend the Company’s amended and restated articles of association accordingly;
3.To approve a reverse split of the Company’s issued and outstanding ordinary shares in the range of a ratio between 1:2 and 1:250, to be effected at the discretion of, at such ratio within the range and by such number of increments, and on such dates, as may be determined by the Company’s board of directors within 18 months following the date of the Meeting;
4.To approve the re-adoption of the compensation policy for the Company’s executive officers and directors;
5.To re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2025 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2024-11-04 |
详情>>
业绩披露：
2024年中报每股收益-1.7美元,归母净利润-344.2万美元,同比去年增长-19.51%
|
| 2024-10-23 |
股东大会：
将于2024-10-23召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Ms. Liat Sidi and Mr. Amnon Ben Shay to serve as Class I directors of the Company, until the Company’s third annual general meeting of shareholders following this Meeting, and until their respective successor is duly elected and qualified.
2.To approve the grant of equity awards to the Company’s Chief Executive Officer.
3.To approve the grant of equity awards to the Company’s President.
4.To approve the grant of equity awards to the Company’s Chairman of the Board.
5.To approve the grant of equity awards to the Company’s directors.
6.To re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accounting firm for the year ending December 31, 2024 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2024-08-22 |
股东大会：
将于2024-10-01召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Ms. Liat Sidi and Mr. Amnon Ben Shay to serve as Class I directors of the Company, until the Company’s third annual general meeting of shareholders following this Meeting, and until their respective successor is duly elected and qualified.
2.To approve the grant of equity awards to the Company’s Chief Executive Officer.
3.To approve the grant of equity awards to the Company’s President.
4.To approve the grant of equity awards to the Company’s Chairman of the Board.
5.To approve the grant of equity awards to the Company’s directors.
6.To re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accounting firm for the year ending December 31, 2024 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-14.43美元,归母净利润-512.2万美元,同比去年增长-97.61%
|
| 2023-10-16 |
详情>>
业绩披露：
2023年中报每股收益-10.85美元,归母净利润-288万美元,同比去年增长49.99%
|
| 2023-08-14 |
股东大会：
将于2023-08-18召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Mr. Amitay Weiss and Mr. Itschak Shrem as a Class III director, to serve until the Company’s third annual general meeting of shareholders following this Meeting, and until their respective successor is duly elected and qualified.
2.To approve a reverse split of the Company’s issued and outstanding ordinary shares at a ratio of up to 1:10, to be effected at the discretion of, and such ratio and on such date to be determined by the board of directors.
3.To re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accounting firm for the year ending December 31, 2023 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2023-07-11 |
股东大会：
将于2023-08-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Mr. Amitay Weiss and Mr. Itschak Shrem as a Class III director, to serve until the Company’s third annual general meeting of shareholders following this Meeting, and until their respective successor is duly elected and qualified.
2.To approve a reverse split of the Company’s issued and outstanding ordinary shares at a ratio of up to 1:10, to be effected at the discretion of, and such ratio and on such date to be determined by the board of directors.
3.To re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accounting firm for the year ending December 31, 2023 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2023-05-01 |
详情>>
业绩披露：
2022年年报每股收益-0.57美元,归母净利润-259.2万美元,同比去年增长55.23%
|
| 2023-05-01 |
详情>>
业绩披露：
2020年年报每股收益-0.1美元,归母净利润-348.2万美元,同比去年增长27.37%
|
| 2022-12-29 |
详情>>
业绩披露：
2022年中报每股收益-1.8美元,归母净利润-575.9万美元,同比去年增长-117.32%
|
| 2022-08-11 |
股东大会：
将于2022-09-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of mr. Lior vider and mr. Alon dayan as a class ii director, to serve until the company’s third annual general meeting of shareholders following this meeting, and until their respective successor is duly elected and qualified;
2.To approve the amended and restated articles of association of the company;
3.To re-appoint kost, forer, gabbay & kasierer, a member of ernst & young global, as our independent registered public accounting firm until the next annual general meeting of shareholders, and to authorize the company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2022-07-07 |
股东大会：
将于2022-08-11召开股东大会
会议内容 ▼▲
- 1.To re-elect each of mr. Lior vider and mr. Alon dayan as a class ii director, to serve until the company’s third annual general meeting of shareholders following this meeting, and until their respective successor is duly elected and qualified;
2.To approve the amended and restated articles of association of the company;
3.To re-appoint kost, forer, gabbay & kasierer, a member of ernst & young global, as our independent registered public accounting firm until the next annual general meeting of shareholders, and to authorize the company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2022-04-28 |
详情>>
业绩披露：
2021年年报每股收益-2.83美元,归母净利润-578.9万美元,同比去年增长-66.26%
|
| 2022-01-06 |
股东大会：
将于2022-02-10召开股东大会
会议内容 ▼▲
- 1.to re-elect Ms. Liat Sidi as a Class I director, to serve until the Company’s third annual general meeting of shareholders following this Meeting, and until her respective successor is duly elected and qualified;
2.to approve a new compensation policy for the Company’s executive officers and directors;
3.to approve an amendment to the compensation terms of the Company’s non-executives directors;
4.to approve the compensation terms of Mr. Itschak Shrem, the President of the Company (and a member of the Board);
5.to approve the compensation terms of Mr. Amitay Weiss, the chairman of the Board;
6.to approve the compensation terms of Mr. Oz Adler, the Company’s Chief Executive Officer;
7.to re-appoint Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accounting firm for the year ending December 31, 2022 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
| 2021-04-02 |
热点提醒：
美股因复活节假期，4月2日休市一天
|
| 2020-09-10 |
股东大会：
将于2020-09-10召开股东大会
会议内容 ▼▲
- 1.To approve the amendments to the amended and restated Articles of Association, as further described in the Proxy Statement.
2.To approve a reverse split of the Company’s ordinary shares by a ratio of up to 20:1, to be effective at the ratio and on a date to be determined by the board of directors, and to amend the Company’s amended and restated Articles of Association accordingly.
|
| 2020-09-10 |
股东大会：
将于2020-09-17召开股东大会
会议内容 ▼▲
- 1.To approve the amendments to the amended and restated Articles of Association, as further described in the Proxy Statement.
2.To approve a reverse split of the Company’s ordinary shares by a ratio of up to 20:1, to be effective at the ratio and on a date to be determined by the board of directors, and to amend the Company’s amended and restated Articles of Association accordingly.
|
| 2020-08-03 |
股东大会：
将于2020-08-04召开股东大会
会议内容 ▼▲
- 1.Re-Election of Directors: To re-elect the currently serving directors (whose names are further described) to the Board of Directors.
2.Appointment of Independent Public Auditor: To re-appoint EY Israel - Kost Forer Gabbay & Kasierer, Certified Public Accountants (Isr.), a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year 2020 and until the next annual general meeting.
3.Increase of Authorized and Registered Share Capital: To approve an increase of the Company’s authorized and registered share capital and to amend the Company’s Articles of Association accordingly.
4.Adoption of the Amended and Restated Articles of Association of the Company: To adopt the amended and restated Articles of Association in order to effect a staggered board mechanism and additional changes as further described in the proxy statement.
5.Approval of Chief Executive Officer’s Employment Agreement and Updating the Chief Financial Officer’s Employment Agreement: To approve (a) the terms of office of the Company’s new Chief Executive Officer as of the beginning of his term as Chief Executive Officer, as further described in the Proxy Statement, and (b) the terms of office of the Company’s Chief Financial Officer as of the same term, as further described in the Proxy Statement.
6.Term of Office of the Newly Appointed Directors: To approve a term of office of each of the Company’s Newly appointed Directors, similar to the term approved to the directors who were reelected at the last annual general meeting.
7.Indemnification and Exculpation Letters to Newly Appointed Directors: To approve that each of Mr. Bar-Lev, Mr. Violette, Prof. Shamiss and Mr. Webber shall be entitled, during and for the duration of their office as directors, to our standard Indemnification and Exculpation letters, in accordance with our compensation policy, all as shall be further described in the Proxy Statement.
8.Removal and Election of Directors.
9.Review of 2019 Annual Financial Statements: To present and review the Company’s Annual Report and annual financial statements for the year ended December 31, 2019, and to transact such other business as may properly come before the Meeting.
|
| 2020-07-31 |
股东大会：
将于2020-07-28召开股东大会
会议内容 ▼▲
- 1.Re-Election of Directors: To re-elect the currently serving directors (whose names are further described) to the Board of Directors.
2.Appointment of Independent Public Auditor: To re-appoint EY Israel - Kost Forer Gabbay & Kasierer, Certified Public Accountants (Isr.), a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year 2020 and until the next annual general meeting.
3.Increase of Authorized and Registered Share Capital: To approve an increase of the Company’s authorized and registered share capital and to amend the Company’s Articles of Association accordingly.
4.Adoption of the Amended and Restated Articles of Association of the Company: To adopt the amended and restated Articles of Association in order to effect a staggered board mechanism and additional changes as further described in the proxy statement.
5.Approval of Chief Executive Officer’s Employment Agreement and Updating the Chief Financial Officer’s Employment Agreement: To approve (a) the terms of office of the Company’s new Chief Executive Officer as of the beginning of his term as Chief Executive Officer, as further described in the Proxy Statement, and (b) the terms of office of the Company’s Chief Financial Officer as of the same term, as further described in the Proxy Statement.
6.Term of Office of the Newly Appointed Directors: To approve a term of office of each of the Company’s Newly appointed Directors, similar to the term approved to the directors who were reelected at the last annual general meeting.
7.Indemnification and Exculpation Letters to Newly Appointed Directors: To approve that each of Mr. Bar-Lev, Mr. Violette, Prof. Shamiss and Mr. Webber shall be entitled, during and for the duration of their office as directors, to our standard Indemnification and Exculpation letters, in accordance with our compensation policy, all as shall be further described in the Proxy Statement.
8.Removal and Election of Directors.
9.Review of 2019 Annual Financial Statements: To present and review the Company’s Annual Report and annual financial statements for the year ended December 31, 2019, and to transact such other business as may properly come before the Meeting.
|
| 2020-06-15 |
详情>>
股本变动：
变动后总股本1408.80万股
|
| 2020-06-15 |
详情>>
业绩披露：
2019年年报每股收益-0.03美元,归母净利润-479.4万美元,同比去年增长43.75%
|
| 2020-06-15 |
详情>>
业绩披露：
2018年年报每股收益-0.06美元,归母净利润-852.3万美元,同比去年增长-36.5%
|
| 2019-12-11 |
股东大会：
将于2020-01-15召开股东大会
会议内容 ▼▲
- 1.Review of 2018 Annual Financial Statements: To present and review the Company’s Annual Report and annual financial statements for the year ended December 31, 2018, and to transact such other business as may properly come before the Meeting.
2.Re-Election of Directors: To re-elect the following currently serving directors to the Board of Directors.
3.Appointment of Independent Public Auditor: To re-appoint EY Israel - Kost Forer Gabbay & Kasierer, Certified Public Accountants (Isr.), a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year 2019 and until the next annual general meeting.
4.Increase of Authorized and Registered Share Capital: To approve an increase of our authorized and registered share capital by NIS 70,000,000 and to amend our Articles of Association accordingly.
5.Amendment of the Company’s Compensation Policy: To approve the Amended Compensation Policy of the Company.
6.Updating Directors’ Terms of Office and Office-Holders’ Terms of Employment re a Change of Control Event: To approve the terms of office and employment, as the case may be, of each of the Directors and Office-Holders of the Company, currently in office.
7.Directors’ and Office-Holders’ Options Grant: To approve the grant of options to Directors and Office-Holders of the Company.
8.Insurance Framework and Ongoing Insurance Policy: To approve the Insurance Framework Terms and the Ongoing Insurance Policy.
|
| 2019-07-23 |
复牌提示：
2019-07-23 10:08:00 停牌，复牌日期 2019-07-23 10:13:00
|
| 2019-01-17 |
股东大会：
将于2019-03-07召开股东大会
会议内容 ▼▲
- 1.To re-elect the following currently serving directors to the Board of Directors, each to serve until the next annual general meeting of shareholders: Dr. Ascher Shmulewitz (Chairman), Amit Berger, Dr. Yafit Stark, Zohar Heiblum, Stephen M. Simes, and Eric So, to hold office as director for an additional term, commencing on the date of the Meeting until the next annual general meeting of shareholders.
2.To re-appoint Kost Forer Gabbay & Kasierer, Certified Public Accountants (Isr.), a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Company’s Board of Directors to determine its compensation for the fiscal year ending December 31, 2018 in accordance with the scope and nature of its services.
3.To present and review the Company’s Annual Report and financial statements for the year ended December 31, 2017, and to transact such other business as may properly come before the Meeting.
|
| 2017-10-25 |
股东大会：
将于2017-11-01召开股东大会
会议内容 ▼▲
- 1.To re-elect the following currently serving directors to the Board of Directors, each to serve until the next Annual General Meeting of shareholders: Dr. Ascher Shmulewitz (Chairman), Amit Berger, Dr. Yafit Stark, Zohar Heiblum, Stephen M. Simes, Mark E. Groussman and Eric So. The voting on this proposal shall be conducted in respect of each director nominee separately.
2.To reappoint Kost Forer Gabbay & Kasierer, Certified Public Accountants (Isr.), a member firm of EY Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2017 and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.
3.To approve in accordance with the Israeli Companies Law, 5759-1999 (the “Companies Law”), the appointment of the Chairman of the Board of Directors, Dr. Ascher Shmulewitz, as Interim Chief Executive Officer, for no additional consideration for his role as Interim Chief Executive Officer.
4.To approve the execution, delivery and performance by the Company of the Second Amendment of the Company’s License Agreement with Dekel Pharmaceuticals Ltd., as amended, pursuant to the form of agreement attached as Annex A to the Proxy Statement, providing for the replacement of all rights to receive royalties, sublicense fees or milestone payments with the right to receive 19,000,000 Ordinary Shares of the Company (equivalent to 475,000 American Depositary Shares (“ADSs”)), subject to meeting all conditions precedent, as further described in the Proxy Statement.
5.To approve an Amended Compensation Policy for Office holders in the form attached as Annex B to the Proxy Statement.
6.With respect to the Board of Directors, to approve:
a.that each of the serving Directors shall, as of October 1, 2017, be compensated total annual Director’s fees (or any part thereof, on a prorated basis) of NIS 120,000, which shall be paid on a quarterly basis;
b.that each of the Directors (whose names are further described), shall be entitled, during and for their office as directors, in addition to customary Director and Officer Insurance, to Indemnification and Exculpation, as further described in the Proxy Statement;
c.the retroactive, one-time cash payment for past services in connection with the Company’s U.S. Initial Public Offering and listing on Nasdaq, to Mr. Stephen Simes and in connection with previous financings rounds to Mr. Abraham Meizler (both directors of the Company) in the amount of $25,000 each.
7.To approve the grant of options to purchase 750,000 Ordinary Shares (equivalent to 18,750 ADSs) to each of the Directors named in Proposal 1 (except for Dr. Shmulewitz, who shall be granted a different number of options) and options to purchase 200,000 Ordinary Shares (equivalent to 5,000 ADSs) to two former Directors, as further described in the Proxy Statement. The voting on this proposal shall be conducted in respect of each director’s grant separately.
8.With respect to the compensation of Ascher Shmulewitz, as the Executive Chairman, and under this capacity alone, to approve:
a.the general terms of Dr. Shmulewitz’s increased compensation and other related terms as a full-time Executive Chairman of the Company commencing retroactively as of July 1, 2017, as further described in the Proxy Statement;
b.the grant of options to purchase 7,150,000 Ordinary Shares (equivalent to 178,750 ADSs) to Dr. Shmulewitz, as further described in the Proxy Statement.
9.With respect to the compensation of Josh Blacher, the Company’s Chief Financial Officer, to approve the following proposals:
a.the general terms of Mr. Blacher’s compensation and other related terms as full-time Chief Financial Officer of the Company, commencing retroactively as of April 12, 2017, as further described in the Proxy Statement;
b.the grant of options to purchase 1,900,000 Ordinary Shares (equivalent to 47,500 ADSs) to Mr. Blacher, as further described in the Proxy Statement.
10.To review the Company’s Annual Report and financial statements for the year ended December 31, 2016, and to transact such other business as may properly come before the Meeting.
|